The impact of the Food and Drug Administration Modernization Act on the recruitment of children for research.
This article argues that contrary to the claims made by research stakeholders in industry, academia and government, the shift in public policy since the enactment of the Food and Drug Administration Modernization Act (FDAMA) of 1997 and its financial incentives to industry to test drugs on children, has had a deleterious impact on children's dignity, health and welfare. Those lucrative incentives offered an opportunity to accelerate the pace of FDA approval for pediatric drug marketing. FDAMA resulted in a radical shift in federal policy to accommodate an expansion of pediatric trials. Children who are precluded from exercising a human adult's right to informed consent to research are increasingly sought as test subjects even when the trials offer no potential benefit for them. Prior to FDAMA children were protected under federal regulations that prohibited their recruitment for experiments that were not in their best interest. This article discusses eight cases and controversies demonstrating that children have been subjected to experiments that exposed them to pain, discomfort, and serious risks of harm. Babies have died testing a lethal heartburn drug; children have been subjected to "forced dose titration" in antidepressant drug trials that resulted in several suicide attempts. Toddlers are currently being subjected to methylphenidate dose tolerance tests without evidence of any pathological condition. Healthy teenagers are being exposed to antipsychotic drugs known to induce severe pathological side effects in speculative "schizophrenia prevention" experiments.
Sharav
Vera Hassner
VH
Alliance for Human Research Protection, c/o Hospital Audiences, Inc., 548 Broadway, 3rd Floor, New York, NY 10012, USA. veracare@ahrp.org
D000293:Adolescent; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D001569:Benzodiazepines; D002648:Child; D002675:Child, Preschool; D020117:Cisapride / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000941:ethics* / Q000331:legislation & jurisprudence*; D016265:Conflict of Interest; D017277:Drug Approval / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000191:economics; D006801:Humans; D007223:Infant; D007880:Legislation, Drug; D040541:Marketing; D008774:Methylphenidate / Q000627:therapeutic use; D033281:Nontherapeutic Human Experimentation / Q000941:ethics; D000077152:Olanzapine; D018579:Patient Selection; D011619:Psychotropic Drugs / Q000627:therapeutic use; D012109:Research Support as Topic; D018570:Risk Assessment; D012559:Schizophrenia / Q000188:drug therapy; D014481:United States; D014486:United States Food and Drug Administration
D000928:Antidepressive Agents; D011619:Psychotropic Drugs; D001569:Benzodiazepines; D008774:Methylphenidate; D000077152:Olanzapine; D020117:Cisapride